v3.25.4
Collaborative and Other Relationships - Syndax (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 52 Months Ended
Aug. 31, 2024
Sep. 30, 2021
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2025
License agreements            
Long term equity investments     $ 47,991 $ 18,814   $ 47,991
Research and development     2,050,152 2,606,848 $ 1,627,594  
Cost of product revenues (including definite-lived intangible amortization)     $ 372,130 312,068 254,990  
Investment in Syndax            
License agreements            
Investment owned (in shares)     1,400,000     1,400,000
Long term equity investments     $ 29,900 18,800   $ 29,900
Unrealized gain (loss) on equity investments     11,100 (11,900) $ (5,500)  
Syndax            
License agreements            
Upfront payment under license agreement           129,500
Research and development     21,900 18,800    
Syndax | Axatilimab - Development Activities            
License agreements            
Accrued and other liabilities     2,400 $ 2,200   2,400
Syndax | Regulatory Milestone            
License agreements            
Milestone payment made under license agreement $ 12,500          
Milestone payment, estimated useful life 10 years          
Syndax | Development and Regulatory Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement     207,500     207,500
Syndax | Commercialization Milestones | Maximum            
License agreements            
Additional milestone payments under the license agreement     $ 225,000     225,000
Syndax | Incyte            
License agreements            
Funding of future development costs     55.00% 55.00%    
Syndax | United States            
License agreements            
Profit share percentage from co-commercialization efforts     50.00%      
Cost of product revenues (including definite-lived intangible amortization)     $ 44,000      
Syndax | United States | Axatilimab - Commercialization Activities            
License agreements            
Accrued and other liabilities     $ 27,600     $ 27,600
Syndax | United States | Syndax            
License agreements            
Funding of future development costs   45.00%        
Syndax | United States | Incyte            
License agreements            
Funding of future development costs   55.00%